= Additional active ingredients
Gatifloxacin 3 mg/ml.
PRESENTATION AND DOSSAGE
OPHTHALMIC SOLUTION: 5 ml
Treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic Gram-Positive bacteria: Corynebacterium propinquum,* Staphylococcus aureus, Staphylococcus epidermidis, streptococcus mitis,* streptococcus pneumoniae. Aerobic Gram-Negative bacteria: Hemophilus influensae. (*Efficacy for these organism was studied in fewer than 10 infections.)
History of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medicdbation.
As with other anti-infectives, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis. Pregnancy and lactation: Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when administered to a nursing mother. Pediatric use: Safety and effectiveness in infants below the age of one year have not been established.
Conjunctival irritation, increased lacrimation, keratitis, and papillary conjunctivitis.
Specific studies have not been conducted.
MANUFACTURER & DISTRIBUTER:
License Holder: Allergan Israel Ltd.